Senior Sales Representative - Spine & Biologics
Current- Manage all aspects of territory (including level-I trauma center) – sales initiatives, case coverage, billing, and inventory- Grew territory from former one-rep operation to team of six (largest in Central Ohio district)Fiscal Year 2024:- Despite surgeon departures mentioned below (accounted for >$2M annual revenue), territory growth was robust- 121% quota attainment- $10.4M annual revenue- 27% revenue Y/Y growth at personally-focused accounts (Q4FY24 revenue >$1M at key account – 105% Y/Y growth, largest quarter of any singular account in territory history)- Drove adoption of new patient-specific / AI-based implant portfolio, became second-highest producer in OhioFiscal Year 2023:- Departure of 3 high-volume surgeons from territory (non-competitive loss of business) – medical retirement, specialty change, resignation- 103% quota attainment- $10.3M annual revenueFiscal Year 2022:- Merged territories with partner to increase bandwidth, allowing for more sales opportunities and growth- $9.3M combined annual revenue (FY18 annual revenue <$2.5M)- 140% revenue Y/Y growth (>$1M) at personally-focused accounts- Sold 4 of 5 new technology releasesFiscal Year 2021:- President’s Club distinction (top 5% of reps – based on revenue growth, sales volume, and quota attainment)- 136% quota attainment (#3 in country)- >$1M territory revenue Y/Y growth- Collaborated with CST partners to close $2.6M in capital sales, driving implant sales at competitive accounts- Sold 8 of 9 new technology releases- Hired and trained SR-I to maintain territory growth; allocated territory funds for neighbor SR-II to cover casesFiscal Year 2020: - 114% quota attainment (133% trend pre-COVID elective procedure shutdown)- >$1M territory revenue Y/Y growth- Sold 7 of 10 new technology releases
